Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?

Ryan A BalkoAndrea Wahner HendricksonMegan E GrudemCarolyn M KlampeAminah Jatoi

Published in: The American journal of hospice & palliative care (2018)

The PARP inhibitors merit further study for chemotherapy-induced peripheral neuropathy. For patients suffering from peripheral neuropathy, these putative palliative effects might prompt earlier consideration of a PARP inhibitor as part of cancer treatment.

Keyphrases

chemotherapy induced
end stage renal disease
dna damage
ejection fraction
dna repair
newly diagnosed
chronic kidney disease
peritoneal dialysis
high glucose
prognostic factors
oxidative stress
diabetic rats
patient reported outcomes
drug induced